Search results
Results From The WOW.Com Content Network
A packet of AstraZeneca COVID-19 vaccine vials. A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, [1] and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol.
The UK-based pharmaceutical firm, known for its popular cancer drugs, entered the Covid-19 crisis with little experience developing vaccines. And the success of Vaxzevria was far from guaranteed .
British finance minister Rachel Reeves wants to reduce state provisions to the company's vaccine centre, which will cut the pledge made by the previous administration from about 90 million pounds ...
London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.
In January 2022, New Scientist reported Sky News-sourced speculation that, "within the coming weeks", the government was expected to announce plans to transition to treating COVID-19 as endemic in the UK. [162] Prime Minister Boris Johnson announced in February 2022 that remaining restrictions would end in England, under a "Living with COVID" plan.
The COVID-19 threat level system was introduced, and the "Stay Home" phase was announced to be equivalent to Level 4 (where 1 meant "COVID-19 is not known to be present in the UK", and 5 meant "The circulation of COVID-19 is high and rising exponentially and there is a material risk of healthcare being overwhelmed"). [citation needed]
The report comes after Britain on Wednesday approved the Oxford-AstraZeneca COVID-19 vaccine, hoping that rapid action will help it stem a record surge of infections driven by a highly contagious ...
The UK COVID-19 Inquiry hears that Boris Johnson proposed injecting himself with COVID-19 on live television during the early days of the pandemic to prove it did not pose a threat to the public. Lord Lister, a former adviser at 10 Downing Street, describes the suggestion as "unfortunate" and "made in the heat of the moment". [216]